SCHEMBL13145362

SCHEMBL13145362

O=C1Nc2ccccc2C1(c1ccc(O)cc1)c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.78
ADORA3 P0DMS8 1/20 0.78
KCNH2 Q12809 1/20 0.78
LMNA P02545 2/20 0.62
MAPT P10636 2/20 0.61
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
XBP1 P17861 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.51
LTA4H P09960 1/20 0.50
NR1H2 P55055 1/20 0.50
BAX Q07812 1/20 0.50
CNR1 P21554 1/20 0.48
HTT P42858 1/20 0.48
GPR35 Q9HC97 1/20 0.48
GPR55 Q9Y2T6 1/20 0.48
MMP2 P08253 5/20 0.44
MMP9 P14780 5/20 0.44
MMP3 P08254 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25502467 0.97 CHRM2 (0.82) CHRM2ADORA3KCNH2LMNAMAPT
SCHEMBL2716060 0.88 CHRM2 (0.93) CHRM2ADORA3KCNH2LMNAMAPT
Oxyphenisatine SCHEMBL239513 0.88 CHRM2 (1.00) CHRM2ADORA3KCNH2LMNAMAPT
Oxyphenisatine SCHEMBL35387956 0.88 CHRM2 (1.00) CHRM2ADORA3KCNH2LMNAMAPT
SCHEMBL11748640 0.86 CHRM2 (0.78) CHRM2ADORA3KCNH2LMNAMAPT
SCHEMBL3198592 0.86 CHRM2 (0.78) CHRM2ADORA3KCNH2LMNAMAPT
SCHEMBL13145364 0.84 CHRM2 (0.85) CHRM2ADORA3KCNH2LMNAMAPT
SCHEMBL25523337 0.84 CHRM2 (0.61) CHRM2ADORA3KCNH2LMNAMAPT
SCHEMBL30685756 0.83 CHRM2 (0.68) CHRM2ADORA3KCNH2LMNAMAPT
SCHEMBL11748631 0.83 CHRM2 (0.72) CHRM2ADORA3KCNH2LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010109008-A1 PRODRUGS OF SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONES TOPOTARGET A/S (DK) 2010-09-30 WO disclosed
US-20100227863-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS TOPOTARGET A/S (DK) 2010-09-09 US disclosed
US-20100227863-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS TOPOTARGET A/S (DK) 2010-09-09 US disclosed
WO-2008129075-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE-COMPOUNDS TOPOTARGET A/S (DK) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100227863-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS TPH2, TPH1, HTR2C CHRM2 1429/4885ADORA3 801/4885KCNH2 4034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.